By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics development firm Nuclea Biotechnologies has closed on a $4.7 million Series B financing round, its President and CEO confirmed to GenomeWeb Daily News.

Patrick Muraca said that the funds will be used for submission of its serum-based fatty acid synthase diagnostic test for prostate cancer to the US Food and Drug Administration for 510(k) clearance. Nuclea anticipates it will submit its application by the end of September, he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.